Results 111 to 120 of about 555,062 (342)

The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia

Haematologica, 2014
Genetic studies in T-cell acute lymphoblastic leukemia have uncovered a remarkable complexity of oncogenic and loss-of-function mutations. Amongst this plethora of genetic changes, NOTCH1 activating mutations stand out as the most frequently occurring ...
Kaat Durinck, Annelynn Wallaert, Inge Van de Walle, Wouter Van Loocke, Pieter-Jan Volders, Suzanne Vanhauwaert, Ellen Geerdens, Yves Benoit, Nadine Van Roy, Bruce Poppe, Jean Soulier, Jan Cools, Pieter Mestdagh, Jo Vandesompele, Pieter Rondou, Pieter Van Vlierberghe, Tom Taghon, Frank Speleman   +17 more
doaj   +1 more source

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

American journal of hematology/oncology, 2018
Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial.
N. Short, E. Jabbour, M. Albitar, M. de Lima, L. Gore, J. Jorgensen, A. Logan, Jae H. Park, F. Ravandi, B. Shah, J. Radich, H. Kantarjian   +11 more
semanticscholar   +1 more source

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia

Haematologica, 2011
Background Mutations in the PHF6 gene were recently described in patients with T-cell acute lymphoblastic leukemia and in those with acute myeloid leukemia.
Qian Wang, Huiying Qiu, Hui Jiang, Lili Wu, Shasha Dong, Jinlan Pan, Wenjuan Wang, Nana Ping, Jing Xia, Aining Sun, Depei Wu, Yongquan Xue, Hans G. Drexler, Roderick A. F. MacLeod, Suning Chen   +14 more
doaj   +1 more source

Height and lymphoblastic leukemia. [PDF]

Archives of Disease in Childhood, 1983
D Taylor, W R McWhirter, K M McWhirter
openaire   +3 more sources

Clinical validation of a real‐time machine learning‐based system for the detection of acute myeloid leukemia by flow cytometry

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Machine‐learning (ML) models in flow cytometry have the potential to reduce error rates, increase reproducibility, and boost the efficiency of clinical labs. While numerous ML models for flow cytometry data have been proposed, few studies have described the clinical deployment of such models.
Lauren M. Zuromski, Jacob Durtschi, Aimal Aziz, Jeffrey Chumley, Mark Dewey, Paul English, Muir Morrison, Keith Simmon, Blaine Whipple, Brendan O'Fallon, David P. Ng   +10 more
wiley   +1 more source

Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia

Haematologica, 2015
In contrast to acute lymphoblastic leukemia in children, adult cases of this disease are associated with a very poor prognosis. In order to ascertain whether the frequencies and patterns of submicroscopic changes, identifiable with single nucleotide ...
Setareh Safavi, Markus Hansson, Karin Karlsson, Andrea Biloglav, Bertil Johansson, Kajsa Paulsson   +5 more
doaj   +1 more source

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage

Cancer, 2018
The outcomes of patients with relapsed or refractory (R‐R) acute lymphoblastic leukemia (ALL) are poor. Inotuzumab ozogamicin and blinatumomab have single‐agent activity in R‐R ALL.
E. Jabbour, K. Sasaki, F. Ravandi, Xuelin Huang, N. Short, Maria R. Khouri, P. Kebriaei, J. Burger, J. Khoury, J. Jorgensen, N. Jain, M. Konopleva, G. Garcia-Manero, T. Kadia, J. Cortes, J. Jacob, Kathryn S. Montalbano, Rebecca E. Garris, S. O'brien, H. Kantarjian   +19 more
semanticscholar   +1 more source

Synthetic Biology‐Based Engineering Living Therapeutics for Antimicrobial Application

Exploration, EarlyView.
This perspective highlights synthetic biology‐driven antibacterial strategies, focusing on three innovative approaches: engineered bacteriophages for precision bacterial targeting, reprogrammed microbes that detect quorum‐sensing signals or metabolites to release antimicrobials, and engineering mammalian cells that recognize pathogen‐associated ...
Shun Huang, Shuihao Zhao, Haijie Zhao, Mingzhang Wen, Zhong Guo   +4 more
wiley   +1 more source

Initial prognostic factors and lymphoblast-erythrocyte rosette formation in 109 children with acute lymphoblastic leukemia [PDF]

, 1977
LW Dow, Luis Borella, L Sen, RJ Aur, SL George, AM Mauer, JV Simone   +6 more
openalex   +1 more source